New QuickMIC® agreement signed for routine use in Bosnia and Herzegovina
The diagnostics company Gradientech and their distributor Biomedica Medizinprodukte, today announces the successful installation of QuickMIC® systems for ultra-rapid antibiotic susceptibility testing (AST) at the Clinical Center University of Sarajevo, one of the largest hospitals in Bosnia and Herzegovina.
The hospital’s clinical microbiology laboratory features a dedicated team committeed to delivering optimal patient care through their expertise and the use of cutting-edge, precise diagnostic solutions.
“We are proud to be among the first in the region to implement the QuickMIC system. This technology allows us to provide ultra-rapid and reliable antibiotic susceptibility results, crucial for timely and effective treatment of our patients,” says Prof. Amela Dedeić Ljubović, MD, PhD, Specialist in Medical Microbiology and Parasitology and Head of the Clinical Microbiology laboratory at the Clinical Center of the University of Sarajevo. “Our team is committed to integrating the latest innovations to improve clinical outcomes and combat antimicrobial resistance. One of the key advantages of this system is its ability to perform testing directly from positive blood cultures, which is particularly vital in emergency situations like sepsis, where prompt intervention is critical for patient survival.”
Biomedica Medizinprodukte, a distributor of in vitro diagnostics, medical devices, clinical IT and life sciences products for over 40 years, is the exclusive distributor of the QuickMIC system in 13 countries across Central and Eastern Europe. “We are proud to be supporting our customers on their journey to faster life-saving treatments and to be cooperating with visionary companies such as Gradientech, a key player in rapid AST”, says Karin Rappich, Country Manager for Biomedica d.o.o in Bosnia and Herzegovina.
The ultra-rapid and precise antibiotic susceptibility testing results of QuickMIC® contribute to timely and effective management of sepsis patients, helping clinicians make faster antibiotic treatment decisions. Its modular design offers affordable scaling possibilities, making QuickMIC suitable for both small and large hospital laboratories. QuickMIC and its gram-negative panel are CE marked and commercially available in Europe but not yet available for sale in the United States.
For further information, please contact:
Sara Thorslund, PhD, CEO
Tel: +46 736 29 35 80
About Gradientech
Gradientech is a leader in ultra-rapid antibiotic susceptibility testing, developing next-generation diagnostics for infectious disease medicine. Our product QuickMIC®, classified as a breakthrough device by the U.S. Food and Drug Administration, contributes to the effective management of sepsis patients by supporting antibiotic treatment decisions in record time. This helps save lives, reduce healthcare costs, and combat the spread of antibiotic resistance – one of our greatest global health threats. Gradientech is headquartered in Uppsala, Sweden. Visit www.gradientech.se for more information.